Polymerase Chain Reaction Assays Reverted to Positive in 25 Discharged Patients With COVID-19
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissionsoup.com..
We report the observation that 14.5% of COVID-19 patients had positive RT-PCR testing again after discharge. We describe correlations between laboratory parameters and treatment duration (P = .002) and time to virus recrudescence (P = .008), suggesting the need for additional measures to confirm illness resolution in COVID-19 patients.
| Errataetall: |
CommentIn: Clin Infect Dis. 2020 Nov 19;71(16):2303-2304. - PMID 32379859 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:71 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 71(2020), 16 vom: 19. Nov., Seite 2230-2232 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yuan, Jing [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 04.12.2020 Date Revised 07.12.2022 published: Print CommentIn: Clin Infect Dis. 2020 Nov 19;71(16):2303-2304. - PMID 32379859 Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciaa398 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM308516370 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM308516370 | ||
| 003 | DE-627 | ||
| 005 | 20231225131910.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciaa398 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1028.xml |
| 035 | |a (DE-627)NLM308516370 | ||
| 035 | |a (NLM)32266381 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yuan, Jing |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Polymerase Chain Reaction Assays Reverted to Positive in 25 Discharged Patients With COVID-19 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.12.2020 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Clin Infect Dis. 2020 Nov 19;71(16):2303-2304. - PMID 32379859 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissionsoup.com. | ||
| 520 | |a We report the observation that 14.5% of COVID-19 patients had positive RT-PCR testing again after discharge. We describe correlations between laboratory parameters and treatment duration (P = .002) and time to virus recrudescence (P = .008), suggesting the need for additional measures to confirm illness resolution in COVID-19 patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a coronavirus | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a D-dimer level | |
| 650 | 4 | |a discharged patients | |
| 650 | 4 | |a recurrent viral activity | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a RNA, Viral |2 NLM | |
| 700 | 1 | |a Kou, Shanglong |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Yanhua |e verfasserin |4 aut | |
| 700 | 1 | |a Zeng, Jianfeng |e verfasserin |4 aut | |
| 700 | 1 | |a Pan, Yanchao |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Lei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 71(2020), 16 vom: 19. Nov., Seite 2230-2232 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:71 |g year:2020 |g number:16 |g day:19 |g month:11 |g pages:2230-2232 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciaa398 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 71 |j 2020 |e 16 |b 19 |c 11 |h 2230-2232 | ||